BioWorld

Dec. 5, 2005

View Archived Issues

DNA-Methylating Enzyme Set To Become Biotech Workhorse

Read More

NeurogesX Adds $20M To Finish Pivotal Transacin Trials In Pain

Read More

Other News To Note

Read More

Inspire's Stock Tanks On Dry Eye Drug's Second Approvable Letter

The FDA dealt another blow to Inspire Pharmaceuticals Inc. with a second approvable letter for its investigational dry eye drug, diquafosol, shaving a third off the company's stock value Friday. (BioWorld Today) Read More

CMS' Demo Project 'Ain't What We Thought It Was,' Says Baird

Read More